Alnylam Pharmaceuticals (ALNY) 2024 Wells Fargo Healthcare Conference summary

Key clinical data and market positioning

• Recent ESC data for Vutrisiran in cardiomyopathy was well received, showing a 31% reduction in all-cause mortality at 33–36 months and 36% at 42 months.

• Efficacy was consistent across subgroups, including those on baseline Tafamidis, with a 65% mortality reduction in milder patients.

• The market opportunity is significant, with 200,000–300,000 potential patients and only a 20% current treatment rate.

• Early aggressive treatment is expected to drive adoption, with a strong switch opportunity from patients inadequately responding to Tafamidis.

• Combination therapy is unlikely to be a major driver until Tafamidis goes generic, expected by end of 2028.

Commercial launch, access, and reimbursement

• Launch is targeted for Q2 2025, with a regulatory filing expected 3–4 months after top-line data and a six-month FDA review using a Priority Review Voucher.

• Vutrisiran will be a Medicare Part B drug, offering most patients zero out-of-pocket costs due to Medigap coverage, compared to Part D drugs with a $2,000 cap.

• Payer management is expected to be more intense for Part D drugs post-IRA, while Part B drugs like Vutrisiran will be less affected.

• Drug administration is flexible, with 25% of patients receiving it at home, 25% at infusion clinics, and 50% in hospital outpatient settings, supporting high compliance rates above 90%.

• Pricing will be unified across indications, with value and patient access as key considerations; specifics to be determined closer to launch.

Competitive landscape and pipeline outlook

• Vutrisiran is expected to have an 18–24 month lead over competitors if AstraZeneca and Ionis complete their studies as planned.

• The next-generation ALN-TTRsc04 compound shows deeper, more durable knockdown and could offer annual or biannual dosing, with phase 3 design details expected by year-end.

• ALN-TTRsc04 has no royalty burden to Sanofi and IP protection into the 2040s, supporting long-term margin expansion.

• The broader pipeline includes a phase 2 hypertension program with Roche, a CNS program with Regeneron, and plans to expand into muscle and adipose tissues.